Kura Oncology, Inc. (KURA) EPS Estimated At $-0.41

October 13, 2018 - By Darrin Black

Kura Oncology, Inc. (NASDAQ:KURA) Logo

Analysts expect Kura Oncology, Inc. (NASDAQ:KURA) to report $-0.41 EPS on November, 6.They anticipate $0.03 EPS change or 7.89 % from last quarter’s $-0.38 EPS. After having $-0.45 EPS previously, Kura Oncology, Inc.’s analysts see -8.89 % EPS growth. The stock increased 1.29% or $0.2 during the last trading session, reaching $15.66. About 161,984 shares traded. Kura Oncology, Inc. (NASDAQ:KURA) has risen 56.76% since October 14, 2017 and is uptrending. It has outperformed by 41.14% the S&P500.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. The company has market cap of $528.89 million. The Company’s pipeline consists of small molecule product candidates that target cancer. It currently has negative earnings. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia.

Another recent and important Kura Oncology, Inc. (NASDAQ:KURA) news was published by Globenewswire.com which published an article titled: “Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable” on September 26, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>